TOT BIOPHARM INTERNATIONAL COMPANY LIMITED

Press Releases TOT BIOPHARM International Company Limited

Equities

1875

HK0000545266

Market Closed - Hong Kong S.E. Other stock markets 01:38:07 09/05/2024 pm IST			5-day change	1st Jan Change
1.87 ^HKD	-1.06%		+7.47%	-5.08%

15/03	TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TOT Biopharm's Loss Narrows in January-September Period	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOP BIOPHARM Shares	01/22/01	AQ
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China	02/21/02	PR
TOT BIOPHARM International : 2021 Interim Revenue Surges 78% to RMB23.13 million	13/21/13	AQ
TOT BIOPHARM International : VOLUNTARY ANNOUNCEMENT - MARKETING APPROVAL FOR MEGESTROL ACETATE ORAL SUSPENSION (TOM218) OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	13/21/13	PU
TOT BIOPHARM International : CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2021	10/21/10	PU
TOT BIOPHARM International : Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020	24/21/24	AQ
TOT BIOPHARM International : Optimises Company Management Structure to Promote Strategic Development Upgrade	16/20/16	AQ
TOT BIOPHARM International : INTERIM REPORT 2020	21/20/21	PU
Form of proxy for use by shareholders at the extraordinary general meeting to be held with the combination of a physical meeting at Unit 1603-1604, 16/F, Causeway Bay Plaza I, 489 Hennessy Road, Causeway Bay, Hong Kong and a virtual meeting online on Friday, 21 August 2020 at 4:00 p.m. (or any adjournment thereof)	31/20/31	PU
TOT BIOPHARM International : VOLUNTARY ANNOUNCEMENT - COMPLETION OF DOSING IN THE FIRST PATIENT FOR THE PHASE III CLINICAL TRIAL OF TAA013, AN ANTIBODY DRUG CONJUGATE	23/20/23	PU
TOT BIOPHARM International : Self-Developed Biological Drug TAB008 (Pusintin) Meets Primary Endpoint in Phase III Clinical Trial	22/20/22	AQ
TOT BIOPHARM International : Announces 2019 Annual Results	18/20/18	AQ
TOT BIOPHARM International : Garners "Listing Award of Technological Company" and "Innovative Technological Research and Development Award"	09/20/09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Stock Market
Equities
1875 Stock
News TOT BIOPHARM International Company Limited
Press Releases

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW